PURPOSE: To assess the efficacy and tolerability of mycophenolate sodium (MPS) in patients with uveitis. METHODS: Retrospective analysis including uveitis patients treated with MPS (Myfortic) for at least 3 months duration. MPS was administered in a dose of 720 mg twice daily. RESULTS: We analyzed 35 patients (65 affected eyes) with anterior (n = 5), intermediate (n = 23), posterior (n = 6), and panuveitis (n = 1). Previous treatment consisted of systemic corticosteroids in all patients and at least one immunomodulating agent in 15 patients. Mean duration of MPS therapy was calculated as 9.6 months (3-31 months). MPS was able to control intraocular inflammation without relapse in 30 patients (85.7%). Stabilization or improvement of visual acuity was achieved in 60 eyes (92.3%). Tolerability of MPS was good or moderate in 34 patients (97.1%). CONCLUSIONS: MPS was demonstrated as an effective and well-tolerated immunosuppressive drug for different forms of uveitis.
PURPOSE: To assess the efficacy and tolerability of mycophenolate sodium (MPS) in patients with uveitis. METHODS: Retrospective analysis including uveitispatients treated with MPS (Myfortic) for at least 3 months duration. MPS was administered in a dose of 720 mg twice daily. RESULTS: We analyzed 35 patients (65 affected eyes) with anterior (n = 5), intermediate (n = 23), posterior (n = 6), and panuveitis (n = 1). Previous treatment consisted of systemic corticosteroids in all patients and at least one immunomodulating agent in 15 patients. Mean duration of MPS therapy was calculated as 9.6 months (3-31 months). MPS was able to control intraocular inflammation without relapse in 30 patients (85.7%). Stabilization or improvement of visual acuity was achieved in 60 eyes (92.3%). Tolerability of MPS was good or moderate in 34 patients (97.1%). CONCLUSIONS:MPS was demonstrated as an effective and well-tolerated immunosuppressive drug for different forms of uveitis.